Pluristem files IND application to begin Phase I critical limb ischemia trial

March 2009
PharmaWatch: Biotechnology;Mar2009, Vol. 8 Issue 3, p10
Market Research Report
The article reports on the investigational drug application filed by Pluristem Therapeutics to the U.S. Food and Drug Administration (FDA) in its aim to commence clinical trial with its placental-derived stromal cell product for the treatment of critical limb ischemia. The firm will begin its Phase I dose ranging clinical trials following the approval of the application. This trial, which is also termed as PLX-PAD, will be conducted during the first half of 2009 at two clinical sites in the U.S.


Related Articles

  • PLURISTEM GETS INTERIM TOP-LINE RESULTS FROM PLX-PAD TRIALS.  // Worldwide Biotech;Jun2010, Vol. 22 Issue 6, p3 

    The article reports on the interim top-line results from the Phase I clinical trials of Pluristem Therapeutics Inc. in Haifa, Israel, in June 2010, which utilize the placenta-derived cell therapy product PLX-PAD for treating critical limb ischemia (CLI). The interim data showed that PLX-PAD is...

  • Regulatory.  // PharmaWatch: Biotechnology;Feb2009, Vol. 8 Issue 2, p9 

    The article offers news briefs on regulatory application and approval related to biotechnology. Pluristem Therapeutics Inc. has filed an application with Paul Ehrlich Institute to start its clinical trials for critical limb ischemia treatment. A drug application was filed by the Neuralstem Inc....

  • Pluristem's Placenta-Derived Cell Therapy Yields Strong Early Data. Boggs, Jennifer // BioWorld Today;4/28/2010, Vol. 21 Issue 81, p1 

    This article reports on the plan of Pluristem Therapeutics Inc. to conduct Phase II testing with its placenta-derived cell therapy treatment PLX-PAD in critical limb ischemia. The Israeli company announced the plan after reporting positive results from two Phase I trials of the treatment,...

  • CLINIC ROUNDUP.  // BioWorld Today;11/18/2009, Vol. 20 Issue 223, p8 

    This section offers news briefs on clinical trials. GlaxoSmithKline PLC, a partner of Anacor Pharmaceuticals Inc., has given six million U.S. dollars to Anacor as a milestone payment for the dosing of the first patient in a Phase I trial of AN3365 for hospital infections caused by Gram-negative...

  • Aastrom Files SPA in Quest for First Cell Therapy in CLI. Young, Donna // BioWorld Today;10/21/2010, Vol. 21 Issue 204, p1 

    The article reports on a special protocol assessment (SPA) filed by Aastrom Biosciences Inc. to the U.S. Food and Drug Administration (FDA) for a Phase III study of its expanded autologous cellular treatment for critical limb ischemia (CLI). According to Aastrom Chief Executive Officer (CEO) Tim...

  • FDA Clinical Hold on PLX Safety Study Trips Pluristem. Powers, Marie // BioWorld Today;6/5/2013, Vol. 24 Issue 107, p1 

    The article reports on the 14.4% decrease in stocks of Pluristem Therapeutics Inc. amid the decision of the U.S. Food and Drug Administration (FDA) to stop the U.S. Phase II study of its Placental expanded cell therapy. Zami Aberman, chairman and chief executive officer of the biotechnology...

  • Wound Care: Treatment Update.  // McKnight's Long-Term Care News;Apr2011, Vol. 32 Issue 4, p8 

    The article offers news briefs related to the medical care industry of the U.S. which include the partnership of Pluristem Therapeutics Inc. with NYU Medical Center, MIST Ultrasound Healing Therapy of Celleration Inc., and the approval of Derma Sciences Inc.'s MediHoney Gel Wound and Burn...

  • New FDA guidelines on clinical trials in women.  // Patient Care;11/15/1993, Vol. 27 Issue 18, p21 

    Reports on the United States Food and Drug Administration's guidelines on clinical trials in women. Drug development tests; Effects of concurrent medications on women; Drug applications.

  • A registry for clinical trials. Chollar, Susan; Chollar, S // Annals of Internal Medicine;04/15/98, Vol. 128 Issue 8, p701 

    Presents information on the legalization of the United States Food and Drug Administration (FDA) Modernization Act of 1997 pertaining to a clinical trial registry. Information on the Public Law 105-115, Item 17: (82), Section 113; Forecast of the registry; Operation under the auspices of the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics